132 related articles for article (PubMed ID: 27524282)
1. Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness.
Fracasso G; Falvo E; Colotti G; Fazi F; Ingegnere T; Amalfitano A; Doglietto GB; Alfieri S; Boffi A; Morea V; Conti G; Tremante E; Giacomini P; Arcovito A; Ceci P
J Control Release; 2016 Oct; 239():10-8. PubMed ID: 27524282
[TBL] [Abstract][Full Text] [Related]
2. The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity.
Falvo E; Malagrinò F; Arcovito A; Fazi F; Colotti G; Tremante E; Di Micco P; Braca A; Opri R; Giuffrè A; Fracasso G; Ceci P
J Control Release; 2018 Apr; 275():177-185. PubMed ID: 29474961
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model.
Damiani V; Falvo E; Fracasso G; Federici L; Pitea M; De Laurenzi V; Sala G; Ceci P
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28718812
[TBL] [Abstract][Full Text] [Related]
4. Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements.
Falvo E; Tremante E; Arcovito A; Papi M; Elad N; Boffi A; Morea V; Conti G; Toffoli G; Fracasso G; Giacomini P; Ceci P
Biomacromolecules; 2016 Feb; 17(2):514-22. PubMed ID: 26686226
[TBL] [Abstract][Full Text] [Related]
5. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of doxorubicin by CSA-binding nanoparticles for choriocarcinoma treatment.
Zhang B; Cheng G; Zheng M; Han J; Wang B; Li M; Chen J; Xiao T; Zhang J; Cai L; Li S; Fan X
Drug Deliv; 2018 Nov; 25(1):461-471. PubMed ID: 29426237
[TBL] [Abstract][Full Text] [Related]
7. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
[TBL] [Abstract][Full Text] [Related]
8. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy.
Wu G; Wang Z; Bian X; Du X; Wei C
Pharm Biol; 2014 Aug; 52(8):978-82. PubMed ID: 25017652
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin.
Falvo E; Tremante E; Fraioli R; Leonetti C; Zamparelli C; Boffi A; Morea V; Ceci P; Giacomini P
Nanoscale; 2013 Dec; 5(24):12278-85. PubMed ID: 24150593
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
Yu D; Li W; Zhang Y; Zhang B
Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
[TBL] [Abstract][Full Text] [Related]
13. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy.
Mou Q; Ma Y; Zhu X; Yan D
J Control Release; 2016 May; 230():34-44. PubMed ID: 27040815
[TBL] [Abstract][Full Text] [Related]
14. Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression.
Lei Y; Hamada Y; Li J; Cong L; Wang N; Li Y; Zheng W; Jiang X
J Control Release; 2016 Jun; 232():131-42. PubMed ID: 27046157
[TBL] [Abstract][Full Text] [Related]
15. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
16. A highly tumor-specific light-triggerable drug carrier responds to hypoxic tumor conditions for effective tumor treatment.
Park W; Bae BC; Na K
Biomaterials; 2016 Jan; 77():227-34. PubMed ID: 26606448
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
